CN101583874B - 利用后叶激素运载蛋白制备对心功能不全进行诊断和危险分层的试剂盒 - Google Patents

利用后叶激素运载蛋白制备对心功能不全进行诊断和危险分层的试剂盒 Download PDF

Info

Publication number
CN101583874B
CN101583874B CN200780045278.9A CN200780045278A CN101583874B CN 101583874 B CN101583874 B CN 101583874B CN 200780045278 A CN200780045278 A CN 200780045278A CN 101583874 B CN101583874 B CN 101583874B
Authority
CN
China
Prior art keywords
purposes according
cardiac insufficiency
insufficiency
mark
diagnosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200780045278.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN101583874A (zh
Inventor
A·贝格曼
J·施特鲁克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BRAHMS GmbH
Original Assignee
BRAHMS GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BRAHMS GmbH filed Critical BRAHMS GmbH
Publication of CN101583874A publication Critical patent/CN101583874A/zh
Application granted granted Critical
Publication of CN101583874B publication Critical patent/CN101583874B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN200780045278.9A 2006-12-08 2007-12-10 利用后叶激素运载蛋白制备对心功能不全进行诊断和危险分层的试剂盒 Expired - Fee Related CN101583874B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102006058266A DE102006058266A1 (de) 2006-12-08 2006-12-08 Diagnose und Risikostratifizierung von Herzinsuffizienz mittels Neurophysin
DE102006058266.7 2006-12-08
PCT/DE2007/002215 WO2008067806A2 (de) 2006-12-08 2007-12-10 Diagnose und risikostratifizierung von herzinsuffizienz mittels neurophysin

Publications (2)

Publication Number Publication Date
CN101583874A CN101583874A (zh) 2009-11-18
CN101583874B true CN101583874B (zh) 2014-06-25

Family

ID=39363234

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200780045278.9A Expired - Fee Related CN101583874B (zh) 2006-12-08 2007-12-10 利用后叶激素运载蛋白制备对心功能不全进行诊断和危险分层的试剂盒

Country Status (6)

Country Link
US (1) US20100093012A1 (enExample)
EP (1) EP2100145B1 (enExample)
JP (2) JP5388858B2 (enExample)
CN (1) CN101583874B (enExample)
DE (1) DE102006058266A1 (enExample)
WO (1) WO2008067806A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5320294B2 (ja) 2006-10-26 2013-10-23 ベー．エル．アー．ハー．エム．エス ゲーエムベーハー プロバソプレシンまたはその断片および部分ペプチド、特にコペプチンまたはニューロフィジンｉｉを使用する、急性冠動脈症候群についてのリスク層化
US20110262939A1 (en) * 2008-10-31 2011-10-27 B.R.A.H.M.S Gmbh Methods and assays for classifying foodstuff and/or beverage and/or diet and/or nutrition regimen and/or medicament in view of an effect on the cardiovascular system
CA2785592A1 (en) * 2010-01-08 2011-07-14 Cavadis B.V. Determination of exosomel biomarkers for predicting cardiovascular events
EP2533052A1 (en) * 2011-06-07 2012-12-12 B.R.A.H.M.S GmbH Diagnostic use of proSomatostatin
JP5802614B2 (ja) * 2012-06-15 2015-10-28 富士フイルム株式会社 臨床情報表示装置および臨床情報表示装置の動作方法並びに臨床情報表示プログラム
JP5802615B2 (ja) * 2012-06-18 2015-10-28 富士フイルム株式会社 臨床情報表示装置および臨床情報表示装置の動作方法並びに臨床情報表示プログラム
US10415094B2 (en) 2016-10-06 2019-09-17 HelicalHelp LLC Risk stratification method for a patient having a polymorphism

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004006860A2 (en) * 2002-07-16 2004-01-22 Woomera Therapeutics, Inc. Compositions and uses thereof for identifying and targeting provasopressin-expressing cancer cells
CN1596120A (zh) * 2001-11-26 2005-03-16 第一三得利制药株式会社 经鼻吸收用药物组合物
EP1628136A1 (en) * 2004-08-19 2006-02-22 B.R.A.H.M.S. Aktiengesellschaft Method of diagnosis of disease using copeptin

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9305142D0 (en) * 1993-03-12 1993-04-28 Medinnova Sf Method
MXPA03004105A (es) * 2002-05-14 2004-10-15 Hoffmann La Roche Elaboracion de una prognosis en casos de enfermedad cardiaca usando una combinacion de marcadores.
EP1530047A1 (en) * 2003-11-07 2005-05-11 Roche Diagnostics GmbH Proximal markers of arterial thrombosis and inflammation for risk stratification of coronary heart disease
EP2302395B1 (en) * 2006-06-07 2015-04-15 Health Diagnostic Laboratory, Inc. Markers associated with arteriovascular events and methods of use thereof
JP5320294B2 (ja) * 2006-10-26 2013-10-23 ベー．エル．アー．ハー．エム．エス ゲーエムベーハー プロバソプレシンまたはその断片および部分ペプチド、特にコペプチンまたはニューロフィジンｉｉを使用する、急性冠動脈症候群についてのリスク層化

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1596120A (zh) * 2001-11-26 2005-03-16 第一三得利制药株式会社 经鼻吸收用药物组合物
WO2004006860A2 (en) * 2002-07-16 2004-01-22 Woomera Therapeutics, Inc. Compositions and uses thereof for identifying and targeting provasopressin-expressing cancer cells
EP1628136A1 (en) * 2004-08-19 2006-02-22 B.R.A.H.M.S. Aktiengesellschaft Method of diagnosis of disease using copeptin

Also Published As

Publication number Publication date
HK1135185A1 (en) 2010-05-28
WO2008067806A3 (de) 2008-09-25
US20100093012A1 (en) 2010-04-15
JP2010511877A (ja) 2010-04-15
JP2013210385A (ja) 2013-10-10
DE102006058266A1 (de) 2008-06-12
EP2100145A2 (de) 2009-09-16
EP2100145B1 (de) 2018-02-28
JP5388858B2 (ja) 2014-01-15
CN101583874A (zh) 2009-11-18
WO2008067806A2 (de) 2008-06-12

Similar Documents

Publication Publication Date Title
JP5320294B2 (ja) プロバソプレシンまたはその断片および部分ペプチド、特にコペプチンまたはニューロフィジンｉｉを使用する、急性冠動脈症候群についてのリスク層化
CN101611314B (zh) 利用新颖标志物CT-proADM进行诊断和危险分层
CN101646945B (zh) 利用CT-proET-1与NT-proBNP的组合进行急性冠状动脉综合征的诊断和风险分层
CN102105794B (zh) 移植物衰竭和死亡的标志物
DK2823314T3 (en) Predicting outcome in patients with chronic obstructive pulmonary disease
CN107015009B (zh) 借助于利尿肽对nyha i级患者进行心功能不全的诊断和危险分层
ES2455191T3 (es) Procedimiento para determinar la parte de la región media de proANP amino-terminal en pacientes que presentan una cardiopatía o que se sospecha que desarrollan o que presentan una cardiopatía
CN101583874B (zh) 利用后叶激素运载蛋白制备对心功能不全进行诊断和危险分层的试剂盒
JP2010526305A (ja) Ｎｔ−プロｅｔ−１を用いる診断およびリスク層別化
CN102652261B (zh) 用于预测心脏手术患者中的肾衰竭的gdf-15和/或肌钙蛋白t
JP4664939B2 (ja) 息切れの心臓原因および肺原因を鑑別するための手段および方法
Tawfeeq et al. The impact of COVID-19 on BNP, NT-proBNP and ANP in heart failure
CN101600967B (zh) 和肽素或后叶激素运载蛋白ii在制备急性冠状动脉综合征危险性分级试剂盒的用途
US20060183174A1 (en) Diagnosis
JP2011523072A (ja) １型糖尿病を有する患者の合併症の評価
HK1135185B (en) Kit for diagnosis and risk stratification of cardiac insufficiency using neurophysin
HK1241025B (zh) 借助於利尿肽对nyha i级患者进行心功能不全的诊断和危险分层
HK1241025A1 (en) Diagnosis and risk stratification of cardiac insufficiency by means of natriuretic peptides for nyha i patients
HK1140547B (en) Diagnosis and risk classification of acute coronary syndrome by means of ct-proet-1 in combination with nt-probnp
HK1118334A (en) Means and methods for the differentiation of cardiac and pulmonary causes of acute shortness of breath
HK1137808B (en) Use of copertin or neurophysin ii in the manufacture of a kit for risk stratification for acute coronary syndrome
HK1140544A (en) Diagnosis and risk stratification of cardiac insufficiency by means of natriuretic peptides for nyha i patients

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1135185

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee

Owner name: BRAHMS CO., LTD.

Free format text: FORMER NAME: BRAHMS AG

CP01 Change in the name or title of a patent holder

Address after: German Hennings Dov

Patentee after: BRAHMS AG

Address before: German Hennings Dov

Patentee before: Brahms AG

REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1135185

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20140625